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ABSTRACT
Cephalosporin‐resistant Escherichia coli has been increasingly reported worldwide. In this study, 32
cephalosporin resistant E. coli isolates identiﬁed from cancer patients in Cairo, Egypt in 2009–2010 were
analyzed. Twenty‐three were of phylogenetic group D, seven A and one each B1 and B2. By rep‐PCR 15
phylogroup D isolates were grouped in four clusters, one with sequence type (ST) 405 and three ST68.
Seventeen isolates showed single patterns. blaCTX‐M‐15 and aac(6')‐Ib‐cr were the most common
resistance determinants. blaOXA‐48 and blaVIM were also detected. Multidrug resistant E. coli seriously
affects healthcare, especially in immunocompromised hosts, such as cancer patients.
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Escherichia coli is a major cause of both community and
healthcare‐associated infections (1, 2). Extra‐intestinal
infections due to E. coli increase morbidity, mortality,
and healthcare costs in hospitalized patients (3). Their
impact can be especially severe in immunocompro-
mised patients, such as cancer patients receiving
chemotherapy (4).
Extended spectrum b‐lactamases, AmpC and
carbapenemase‐producing E. coli have been reported
worldwide (2). PMQR genes have also been increasingly
reported (5, 6). To date, at least three types of PMQR
determinants, namely qnr families, aac(60)‐Ib‐cr and
quinolone efﬂux pump (qepA and oqxAB) have been
extensively described in E. coli (3, 5, 6). In particular, qnr
genes have been frequently detected among isolates
producing ESBLs (6). Additionally, a close association
between aac(60)‐Ib‐cr and CTX‐M‐15, an ESBL that has
emerged worldwide, has been reported by many
epidemiological studies (6). Recent studies in Egypt
have reported a high prevalence of CTX‐M‐15 encoding
genes among different E. coli clones in community and
hospital settings (7, 8). The aim of this study was to
investigate the molecular epidemiology and resistance
determinants pattern of cephalosporin resistant E. coli
isolates identiﬁed from cancer patients in Cairo, Egypt in
2009–2010.
A retrospective analysis of E. coli isolates from clinical
samples was performed at the National Cancer Institute,
Cairo, Egypt, from January 2009 to June 2010. Identiﬁ-
cation and antimicrobial susceptibility testing of gram‐
negative isolates had been performed in the microbiology
laboratories of the hospitals of origin by routine methods.
Thirty‐two of 73 viable isolates (43.8%)were selected after
ESBL production screening according to the following
MIC breakpoints: cefotaxime, 8 mg/L; ceftazidime,
2 mg/L and aztreonam, 8 mg/L (9). Duplicate isolates
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from the same patient with indistinguishable susceptibility
patterns were excluded. Basic demographic and clinical
datawere obtained from the databases of themicrobiology
laboratories. Because the study consisted of a retrospective
review of routine microbiological data that were analyzed
anonymously, approval by the Ethics Committee and
informed consent were not required.
Minimum inhibitory concentrations of amoxicillin–
clavulanic acid, cefotaxime, ceftazidime, imipenem,
meropenem, gentamicin and ciproﬂoxacin of the 32
selected isolates were assessed by E‐test (Biomérieux,
Marcy l'Etoile, France). Assignment of E. coli phylogenetic
groups was performed by the triplex PCR assay described
by Clermont et al. (10). Clonal relationships were
established by rep‐PCR ampliﬁcation using the Diversi-
Lab Escherichia ﬁngerprinting kit (BioMérieux) according
to the manufacturer's instructions (11). Rep‐PCR
products were detected and sized using microﬂuidic
LabChips placed on an Agilent 2100 bioanalyzer (Agilent
Technologies, Diegem, Belgium). DNA fragment patterns
were then analyzed by using Pearson correlation
coefﬁcient pairwise pattern matching and the UPGMA
clustering algorithm. Representative E. coli isolates of
the four rep‐PCR clusters, unclustered phylogroup D
isolates and two additional isolates of special epidemio-
logical interest were characterized by MLS) using the
Achtman typing scheme (http://mlst.ucc.ie/mlst/dbs/
Ecoli) according to the protocols published on the
website.
A set of sixmultiplex PCRswas used to screen the isolates
for OXA‐1‐like broad‐spectrum b‐lactamases, CTX‐M,
SHVand TEM, plasmid‐mediated AmpC b‐lactamases and
class A, B and D carbapenemases (12). New Delhi metallo‐
b‐lactamase 1 was searched for using speciﬁc primers (13).
PMQRgenes qnrA, qnrB, qnrC, qnrD, qnrS, qepA and aac(6')‐Ib‐
cr were investigated by PCR as previously described (5).
Identity of the b‐lactamase and quinolone resistance genes
was conﬁrmed by DNA sequence analysis.
Twenty‐seven of the 31 isolates for which information
was available were from adult and four from pediatric
cases. All but one patient were hospitalized and 24 were
receiving imipenem treatment. There was only one
instance of two isolates with different susceptibility
patterns from the same patient. A high proportion of
isolates was from fecal samples (14/31), followed by
exudates and blood (6 and 5, respectively) and other
normally sterile sites.
All isolates were conﬁrmed by E‐test to be resistant to
cefotaxime and/or ceftazidime. Only one isolate was
resistant to carbapenems. Fourteen and 24 isolates were
resistant to gentamicin and ciproﬂoxacin, respectively.
The E. coli isolates were unevenly distributed into the four
phylogenetic groups, 23 belonging to group D, 7 to A and 1
each to B1 and B2 (Table 1). Consistent with previous
reports from Egypt and other low‐resource countries,
phylogroups A and D were predominant, whereas the
hyperepidemic strain B2‐ST131 was under‐represented (8).
Rep‐PCR ﬁngerprinting enabled the identiﬁcation of
four clusters, including 15 phylogroup D isolates, and 17
single patterns (Fig. 1). This suggests that the observed
over‐representation of phylogroup D might be at least
partially explained by intra‐hospital cross‐transmission.
In contrast, the heterogeneity of group A isolates which,
along with group B1, are reportedly frequently associated
with commensal organisms, suggests a prominent
epidemiological role for this phylogroup in the region
under study. According to MLSTone cluster belonged to
ST405 and the remaining three to ST68. All but one of the
non‐clustered phylogroup D isolates were also attributed
with ST68. Isolates D/ST405 have been repeatedly
reported to express a multiresistant phenotype (2, 8).
In contrast, isolates D/ST68 carrying blaCTX‐M‐15 and aac
(6')‐Ib‐crwere an unexpected ﬁnding. Indeed, only twoD/
ST68 isolates containing blaCMY‐2 have been reported
recently, both from wild coastline birds in Miami Beach,
Florida, USA (14). The B2 strain belongs to the
worldwide spread ST131 (2).
All but one isolate in cluster 1 and 13 non clustered
isolates showed a blaCTX‐M‐15 gene, which was consistent
with the global predominance of this ESBL (2). SHV‐12
and CMY‐2 were detected in only four and three
non‐clustered isolates, respectively. Three isolates
co‐produced OXA‐48 and/or VIM carbapenemases
(Table 1). Although carbapenemases have been infre-
quently detected in E. coli, recently some reports have
highlighted the emergence of blaOXA‐48 and blaVIM
carrying isolates (15, 16). Recently, OXA‐48‐producing
E. coli identiﬁed in France from patients transferred from
Egypt were described (16). Our ﬁndings thus conﬁrm the
hypotheses about a likely endemic circulation of OXA‐48
in Egypt and other north African countries (16).
Of special interest, the carbapenem‐resistant isolate
of phylogroup B1 containing blaCMY‐2, blaOXA‐48 and
blaVIM‐29 was attributed with ST101. This supports the
concerning evidence of a previous study by Mushtaq et al.
who reported that 9/18 isolates of NDM‐producing E. coli
from England, Pakistan and India were B1‐ST101 (17).
Finally, ciproﬂoxacin resistance was associated with the
presence of qnrS in only two phylogroup A isolates,
whereas in all the remaining strains aac(6')‐Ib‐cr was
detected (Table 1). Twenty of 27 ciproﬂoxacin resistant E.
coli isolates showed an association with blaCTX‐M‐15 and
aac(6')‐Ib‐cr genes. Thus, the genetic makeup which has
driven the success of the ST131 pandemic clone appears
to be diffuse among E. coli strains of different lineages and
habitats.
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Cephalosporin resistant E. coli in Egypt
Acquisition of multidrug resistance gene traits by a
widely disseminated human commensal organism on a
global scale may seriously affect human health and
healthcare resources by causing difﬁcult‐to‐treat infec-
tions in both community and healthcare settings, thus
increasingly fueling the antibiotic crisis (1, 2). The impact
may be devastating in limited resource countries and
immunocompromised hosts, such as cancer patients. A
previous report from Egypt described rates of resistance
to third generation cephalosporins of approximately 60%
in bloodstream isolates of E. coli from ﬁve hospitals in
Cairo, Egypt in 1999–2000 (18). Our ﬁndings conﬁrm an
alarming picture of multidrug resistance in E. coli and
highlight acquisition of a variety of resistance genetic
determinants in association with PMQR genes and the
emergence of resistance to carbapenems.
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